NORAPS: Noradrenaline for Progressive Supranuclear Palsy Syndromes
NORAPS - A Randomised, Double-Blind, Placebo-Controlled, Crossover Design Clinical Trial to Evaluate the Efficacy and Safety of Oral Atomoxetine for the Treatment of Behavioural and Cognitive Change in Progressive Supranuclear Palsy Syndromes.
Professor James B. Rowe (Professor of Cognitive Neurology and Consultant Neurologist), Department of Clinical Neurosciences.
Cambridge Centre for Parkinson-Plus
Cambridge University Hospitals Trust and University of Cambridge
Health Condition or Problem Studied:
Participants with a confirmed diagnosis of possible or probable progressive supranuclear palsy, including the phenotypic variants of PSP-Richardson Syndrome (PSP-RS), PSP Frontal Variant (PSP-F), PSP with Corticobasal Syndrome (PSP-CBS), PSP with Speech and Language Deficits (PSP-SL), and PSP-RS following initial presentation of Progressive Gait Freezing (PSP-PGF); under the Movement Disorders Society (MDS) criteria (Höglinger et al., 2017).
Investigational medicinal product and dosage:
Atomoxetine 40mg (10 ml of 4mg/ml Oral solution), once daily
Active comparator product:
This study is a Phase IIb, randomised, controlled, crossover design clinical trial
Target Sample Size:
84 participants and 84 suitable informants